Rebisufligene etisparvovec: The first AAV9-mediated SGSH gene therapy approved for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA)
Drug Discoveries & Therapeutics · 31.10.2026 · 20 (5) · 403-404
DOI: 10.5582/ddt.2026.01082 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Discoveries & Therapeutics, erschienen am 31.10.2026. Verfasst von Chen Pang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China. Hauptthemen laut MEDLINE: Mucopolysaccharidosis III, Genetic Therapy, Dependovirus, Hydrolases. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China.
Zitieren
APA
Pang, C., Sun, Y., & Gao, J. (2026). Rebisufligene etisparvovec: The first AAV9-mediated SGSH gene therapy approved for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA). Drug Discoveries & Therapeutics, 20(5), 403-404. https://doi.org/10.5582/ddt.2026.01082
Vancouver
Pang C, Sun Y, Gao J. Rebisufligene etisparvovec: The first AAV9-mediated SGSH gene therapy approved for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA). Drug Discoveries & Therapeutics. 2026;20(5):403-404. doi:10.5582/ddt.2026.01082
BibTeX
@article{Pang2026,
author = {Pang, Chen and Sun, Yueyi and Gao, Jianjun},
title = {Rebisufligene etisparvovec: The first AAV9-mediated SGSH gene therapy approved for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA)},
journal = {Drug Discoveries & Therapeutics},
year = {2026},
volume = {20},
number = {5},
pages = {403--404},
doi = {10.5582/ddt.2026.01082}
}
EUVIMED